Greenwich LifeSciences

About Greenwich LifeSciences

Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy vaccine designed to prevent breast cancer recurrences in HER2-positive patients by activating the immune system.

Products & Services

GLSI-100:A first-of-its-kind immunotherapy vaccine combining GP2 (a HER2/neu-derived peptide) with GM-CSF, aimed at preventing breast cancer recurrence in HER2-positive patients, currently in a Phase III clinical trial (Flamingo-01).

Specialties

Immunotherapy Breast Cancer Prevention HER2-positive Cancer Treatment Clinical Trials

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Financing T: - FT: Equity Financing	A: 7000000 MR: - FA: approximately $7 million FAN: 7000000	D: 2026-01-27 FD: 2026-01-27	2 investors
2	RT: Private Placement T: - FT: Private Placement	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2024-06-14 FD: 2024-06-14	1 investors

Equity Financing Latest

2026-01-27

$7.0M

2 investors (Pro only)

Private Placement 2024-06-14

$2.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Snehal S. Patel

Chief Executive Officer, Board Member

F

F. Joseph Daugherty

Chief Medical Officer, Board Member

J

Jaye Thompson

VP Clinical & Regulatory Affairs

C

Christine T. Fischette

VP Business Development

D

David B. McWilliams

Chairman of the Board

E

Eric Rothe

Founder, Board Member

View 4 more team members with Pro

Unlock Full Team Directory

Recent News